These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23664523)

  • 1. B-cell depletion in immune thrombocytopenia.
    Godeau B
    Semin Hematol; 2013 Jan; 50 Suppl 1():S75-82. PubMed ID: 23664523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is B-cell depletion still a good strategy for treating immune thrombocytopenia?
    Godeau B; Stasi R
    Presse Med; 2014 Apr; 43(4 Pt 2):e79-85. PubMed ID: 24636845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
    Cooper N; Stasi R; Cunningham-Rundles S; Feuerstein MA; Leonard JP; Amadori S; Bussel JB
    Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
    Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study.
    Liebman HA; Saleh MN; Bussel JB; Negrea OG; Horne H; Wegener WA; Goldenberg DM
    Br J Haematol; 2013 Sep; 162(5):693-701. PubMed ID: 23829485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
    Zhou Z; Yang R
    Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell compartment as the selective target for the treatment of immune thrombocytopenias.
    Zaja F; Vianelli N; Sperotto A; De Vita S; Iacona I; Zaccaria A; Masolini P; Tomadini V; Tani M; Molinari AL; Baccarani M; Fanin R
    Haematologica; 2003 May; 88(5):538-46. PubMed ID: 12745273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia.
    Cooper N; Stasi R; Cunningham-Rundles S; Cesarman E; McFarland JG; Bussel JB
    Br J Haematol; 2012 Aug; 158(4):539-47. PubMed ID: 22775462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD20 monoclonal antibodies: beyond B-cells.
    Avivi I; Stroopinsky D; Katz T
    Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
    Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
    Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
    Ratanatharathorn V; Pavletic S; Uberti JP
    Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immune thrombocytopenic purpura: pathophysiology and treatment].
    Godeau B
    Transfus Clin Biol; 2009 May; 16(2):101-5. PubMed ID: 19409827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.
    Quartuccio L; Lombardi S; Fabris M; Masolini P; Saracco M; Pellerito R; De Vita S
    Ann N Y Acad Sci; 2009 Sep; 1173():692-700. PubMed ID: 19758217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
    Aggarwal A; Catlett JP
    South Med J; 2002 Oct; 95(10):1209-12. PubMed ID: 12425512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
    Stübgen JP
    J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency.
    Carbone J; Escudero A; Mayayo M; Ballesteros M; Perez-Corral A; Sanchez-Ramon S; Sarmiento E; Micheloud D; Fernandez-Cruz E
    Ann N Y Acad Sci; 2005 Jun; 1051():666-71. PubMed ID: 16127007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
    Roccatello D; Vangelista A; Pani A
    G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B cell monitoring of transplant patients treated with anti-CD20.
    Abdallah KO; Prak ET
    Clin Transpl; 2006; ():427-37. PubMed ID: 18365400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term treatment of rheumatoid arthritis with rituximab.
    Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
    Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.